Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Other

Abemaciclib

Tracked across 1 events · 6 articles · First seen Sep 18, 2026 · Last active Sep 19, 2026

Sentiment
15
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 15
Regulatory
Eli Lilly and Company announced that the U.S. United States — Food and Drug Administration granted full approval to Inluriyo (imlunestrant), an oral estrogen receptor antagonist, in combination with Abemaciclib (abemaciclib), a CDK4/6 inhibitor, for…
Impact: Abemaciclib gains an additional approved combination use, broadening its label and potential patient population in ESR1-mutated breast cancer.
Sep 18, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Abemaciclib live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.